Access to Innovation in Switzerland: Change Needed
Industry stakeholders are raising the alarm about access to innovative medicines in Switzerland. Do delays in market access compared to other countries in Europe not only threaten the health of…
Founded in 1950 vips is the association of pharmaceutical companies operating in Switzerland, which represents the interests of its members in the relevant Swiss audiences. The focus is on the patient benefits, security of supply, to fair pricing, ensuring fair and pro-business environment, efficient processes in the management and protection of intellectual property.
Contact
vips – Association of Pharmaceutical Companies in Switzerland
Baarerstrasse 2
Postfach 7856
CH-6302 train
Phone: +41 41 727 67 80
Fax: +41 41 727 67 90
Email: info@vips.ch
Homepage: www.vips.ch
Industry stakeholders are raising the alarm about access to innovative medicines in Switzerland. Do delays in market access compared to other countries in Europe not only threaten the health of…
Switzerland is a highly decentralised nation where much of the decision-making power lies within individual Cantons and where the Federal presidency is rotated annually. To consistently keep industry interests on…
Switzerland’s healthcare system is globally renowned. It leads the world on metrics such as infrastructure, medical advances, and patient freedom to choose healthcare services, and ranks 1st in US thinktank…
Switzerland is widely praised for its excellent universal healthcare system and strong pharma sector. Seen as a bastion of efficiency and innovation, the country is nonetheless falling behind its European…
Ernst Niemack, managing director of vips, the association representing pharmaceutical companies operating in Switzerland, comments on the government’s latest cost containment measures such as mandatory rebates and new rules for…
This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss pharma market, featuring data snapshots, feature articles, exclusive interviews…
Marcel Plattner, president of Swiss industry association vips discusses pricing, market access and innovation, as well as the continuing attractiveness of Switzerland as a pharmaceutical investment destination. Attractive conditions…
Susanne Hoeppner, GM of Astellas Switzerland and board member of vips, discusses her key priorities, the culture of Swiss pharma, and the industry-wide push for faster approval times. Ms. Hoeppner,…
Not all impactful innovation involves the development of new chemical or biological entities, and the value of such innovation must be recognized in pricing processes argues Gebro Pharma Switzerland CEO…
Walter P. Hölzle, president of vips, discusses the current priorities of the association, the importance of innovation, and the challenges of the current pricing system. While growth is close to…
See our Cookie Privacy Policy Here
